The growth hormone fragment that promised fat loss vs the GLP-1 that actually delivers it.
Bottom line: This is not a close comparison. AOD-9604 was a promising idea — isolate the fat-burning part of growth hormone without the side effects — but it failed clinical trials. Semaglutide works, is approved, and produces significant weight loss. AOD-9604 persists in the peptide space largely on marketing and hope. If your goal is fat loss, semaglutide is in a completely different league.
| AOD-9604 | Semaglutide | |
|---|---|---|
| Category | HGH fragment (amino acids 176-191) | GLP-1 receptor agonist |
| Mechanism | Modified fragment of human growth hormone designed to stimulate lipolysis (fat breakdown) without affecting blood sugar or promoting growth | Activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve insulin sensitivity |
| Reported dose | 250–500 mcg/day subcutaneous (fasted) | 0.25–2.4 mg weekly injection |
| Frequency | Daily injection, typically morning on empty stomach | Once weekly injection |
| Weight loss (trials) | Failed to demonstrate significant weight loss in clinical trials — modest fat loss at best | ~15% body weight loss at 68 weeks (STEP 1, 2.4 mg) |
| Top side effect | Generally well-tolerated — mild headache, injection site irritation | Nausea, vomiting, diarrhea during dose titration |
| Evidence tier | Tier 4 — failed Phase 2b clinical trial for obesity, no therapeutic application established | Tier 1 — massive RCT program, FDA-approved, millions of prescriptions |
| Common vial size | 5 mg vials | 5 mg or 10 mg vials (compounded) |
| Approval status | Not FDA-approved. Failed clinical development. GRAS status for food use in Australia only | FDA-approved as Ozempic (diabetes), Wegovy (weight loss) |
Honestly, it is hard to make a strong case for AOD-9604 for weight loss when it failed its own clinical trial. Some people add it to stacks for a minor lipolytic edge, but the evidence does not support using it as a primary weight loss intervention. The 'no appetite suppression' angle appeals to people who want to lose fat without appetite changes, but that is also why the results are modest.
Semaglutide is the obvious choice for anyone serious about weight loss. It works through the central mechanism that actually drives obesity (appetite and food noise), has the largest evidence base of any weight loss drug, and produces 5–10x the weight loss AOD-9604 showed in trials.
This is not a close comparison. AOD-9604 was a promising idea — isolate the fat-burning part of growth hormone without the side effects — but it failed clinical trials. Semaglutide works, is approved, and produces significant weight loss. AOD-9604 persists in the peptide space largely on marketing and hope. If your goal is fat loss, semaglutide is in a completely different league.
← Browse all peptides | All comparisons →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify